Breast Lump History Taking OSCE — Red Flags, Triple Assessment & Risk Factors

Why Breast Lump History Is Tested in OSCEs

Breast lump history is a core OSCE station because it tests several competencies simultaneously: systematic symptom characterisation, red flag recognition, sensitive communication, and knowledge of the triple assessment pathway. Breast cancer is the most common cancer in UK women, making this a clinically vital and frequently examined skill.

Opening the Consultation

Introduce yourself, check the patient's name and date of birth, and establish rapport with an empathic opener: "I understand you've noticed something in your breast — that must have been worrying. Can you tell me a bit more about what you've found?" Allow the patient to speak freely before moving to structured questions.

SOCRATES for the Breast Lump

Apply SOCRATES systematically:

Red Flags for Malignancy

Associated Symptoms

Ask specifically about:

• Nipple discharge: colour (clear, milky, green, blood-stained), unilateral vs. bilateral, spontaneous vs. expressed, single duct vs. multiple ducts
• Skin changes: dimpling, redness (inflammatory carcinoma), oedema (peau d'orange), skin tethering, ulceration
• Nipple changes: inversion, eczema-like rash (Paget's disease of the nipple)
• Axillary symptoms: lump, arm swelling (lymphoedema)
• Systemic symptoms: weight loss, bone pain, persistent headaches, breathlessness (metastatic disease)

Menstrual and Hormonal History

• Last menstrual period (is the patient perimenopausal or postmenopausal?)
• Oral contraceptive pill use (modest increased risk)
• Hormone replacement therapy (combined HRT increases risk)
• Pregnancy and breastfeeding history (nulliparity and late first pregnancy increase risk; breastfeeding is protective)

Breast Cancer Risk Factors

Systematically screen:

Past Medical and Drug History

Previous breast biopsies or surgeries, mammography results, prior radiation therapy, and all current medications (especially HRT and OCP).

The Triple Assessment Concept

Explain to the examiner (or patient if asked) that any breast lump requires triple assessment:

1. 1Clinical — history and examination
2. 2Radiological — ultrasound (<35 years) or mammogram (≥35 years) ± MRI
3. 3Pathological — core needle biopsy or fine needle aspiration cytology (FNAC)

A lump is only reassured as benign when all three components are concordantly benign.

Closing the Consultation

Summarise, explore ICE thoroughly ("What was your main worry when you felt the lump?"), and explain the next step. Safety-net clearly: "If the lump gets bigger, the skin changes, or you notice any of those symptoms we discussed before your appointment, please come back immediately or attend A&E."

Mark-Scheme Checklist

Frequently Asked Questions

"What features in the history most suggest breast malignancy versus a benign lump?"

Malignant features: hard, irregular texture; non-mobile (fixed to skin or chest wall); steady growth unrelated to menstrual cycle; associated skin changes (dimpling, peau d'orange); new nipple inversion; blood-stained nipple discharge; axillary lymphadenopathy; and systemic features (weight loss, bone pain). Benign features: soft or rubbery texture, smooth margins, mobile ("breast mouse"), fluctuation with menstrual cycle (fibrocystic change), cyclical pain, tender lump, bilateral or multiple lumps, younger age. Fibroadenomas are the most common benign lump in women under 30. However, benign clinical features do not exclude malignancy — all discrete lumps require triple assessment.

"What is Paget's disease of the nipple and how does it present?"

Paget's disease of the nipple is a form of breast cancer involving the nipple-areola complex. It presents as an eczema-like rash of the nipple — erythema, scaling, and weeping — that does not respond to topical treatments. Unlike eczema, which usually affects the areola first, Paget's disease starts at the nipple. It is associated with underlying ductal carcinoma in situ (DCIS) or invasive breast cancer in >90% of cases. In the history, ask specifically about nipple skin changes. It is commonly misdiagnosed as eczema initially, causing diagnostic delay. Any persistent unilateral nipple rash should be biopsied.

"How do I approach asking about family history of breast cancer in an OSCE?"

Ask about first-degree relatives (mother, sister, daughter) and second-degree relatives (grandmother, aunt), specify which side of the family (maternal or paternal), age at diagnosis, bilateral disease, and any known BRCA mutations. Also ask about ovarian cancer (associated with BRCA1/2), male breast cancer (BRCA2), and other cancers (colorectal in BRCA2 families). A significant family history triggers referral to a clinical genetics service for risk assessment and possible genetic testing. In the UK, NICE CG164 sets out criteria for genetic referral. Women at high risk may be offered risk-reducing measures including chemoprevention with tamoxifen or risk-reducing surgery.

"What is the two-week wait pathway for breast lumps and when does it apply?"

The two-week wait (2WW) cancer referral pathway aims to ensure that patients with suspected cancer are seen by a specialist within 14 days of GP referral. For breast lumps, 2WW applies to: any patient aged 30 or over with an unexplained breast lump; any patient of any age with skin changes suggesting breast cancer; any patient aged 50 or over with unilateral nipple discharge, retraction, or other nipple changes. Once referred, the patient is seen in a one-stop breast clinic where clinical examination, imaging, and biopsy are completed in a single visit — this is the triple assessment process. In the OSCE, stating the 2WW pathway and its rationale demonstrates understanding of the cancer care pathway.

"How does nipple discharge differentiate between benign and malignant causes?"

Blood-stained, unilateral, single-duct, spontaneous discharge is the most concerning pattern and mandates urgent investigation for malignancy (intraductal papilloma or carcinoma). Bilateral, milky discharge in a non-pregnant, non-breastfeeding woman suggests galactorrhoea (check prolactin — pituitary adenoma, antipsychotics, metoclopramide). Green or dark discharge from multiple ducts is typical of fibrocystic change or duct ectasia, which are benign. Clear watery discharge can be associated with carcinoma. The key discriminators in the OSCE are: unilateral vs. bilateral, single duct vs. multiple ducts, spontaneous vs. expressed, and colour (blood-stained = urgent).

"What should I say to a patient who is frightened about the possibility of breast cancer?"

Acknowledge their fear directly and early: "I can completely understand why finding a lump is frightening — it's a very natural response." Avoid false reassurance before assessment is complete. Explain the process clearly: "Most lumps turn out not to be cancer, but we always take them seriously and investigate fully so we can be sure." Describe the triple assessment process in lay terms — "We'll look at the lump, do some scans, and if needed take a small sample" — so the patient knows what to expect. Confirm the timeline (2WW appointment within 14 days) and give a direct contact number for questions. Offer a support leaflet (Breast Cancer Now has excellent patient resources). Demonstrating empathy, clarity, and a clear safety net plan scores well on communication domains.

Related guides: Breast Examination OSCE · Breaking Bad News OSCE Guide · Lymph Node Examination OSCE · Weight Loss History OSCE